Home » Archive by Category

News

San Diego biotech news from BioSpace, Xconomy, PR Newswire, Marketwired and other sources, click on headlines to read the full story.

San Diego Life Sciences Roundup: Ambit, Zogenix, Aethlon, and More

October 3, 2014 – 6:40 am | Edit Post

Assessing the extent of long-term brain damage from concussions in football and other impact sports can be difficult (to say the least) if the only way to determine whether an individual is suffering…

[[Click headline to continue reading.]]

Neurocrine Announces Expansion Of VMAT2 Inhibitor Program With Initiation Of Tourette Syndrome Clinical Study

October 2, 2014 – 1:02 pm | Edit Post

SAN DIEGO, Oct. 2, 2014 /PRNewswire/ — Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it has initiated a clinical trial of NBI-98854, a proprietary small molecule Vesicular Monoamine Transporter 2 (VMAT2) inhibitor, in both children and adolescents with Tourette syndrome.

2014 Pedal the Cause San Diego was a phenomenal success

October 2, 2014 – 12:01 pm | Edit Post

Team Sanford-Burnham, along with more than 750 riders, crossed the finish line to thundering applause and enthusiastic cheers on Sept. 21 as the second annual Pedal the Cause San Diego bike event came to a successful end.

Convocation Keynote Encourages Students to Recognize Power They Have to Influence Others

October 2, 2014 – 6:00 am | Edit Post

Mahatma Gandhi had a saying that he used to mobilize millions of poor people in India to gain independence: “You must be the change you wish to see in the world.”

Diabetes in a Dish

October 1, 2014 – 2:27 pm | Edit Post

Researchers at University of California, San Diego School of Medicine are co-recipients of a $4.1-million grant from the National Institutes of Health to advance treatments for type 1 diabetes. Using human stem cells, the team plans to culture bits of human pancreas in a dish and, using microfluidics, mimic blood flow through the islet.

Health Care and Construction Workers Create Pink Ribbon For Breast Cancer Awareness

September 30, 2014 – 1:55 pm | Edit Post

More than 600 health care and construction workers donned pink hard hats while forming a giant human ribbon at the UC San Diego Jacobs Medical Center construction site today in support of National Breast Cancer Awareness month.

Phase III Clinical Trial to Evaluate Calcium Channel Blocker for Parkinson’s

September 30, 2014 – 10:36 am | Edit Post

Phase III Clinical Trial to Evaluate Calcium Channel Blocker for Parkinson’s

Researchers at the University of California, San Diego School of Medicine have launched a Phase III clinical trial to evaluate the drug isradipine, a calcium channel blocker often used to treat high blood pressure, as a potential new treatment for Parkinson disease. The goal of the study is to determine whether the drug can slow the progression of the disease by keeping the brain’s dopamine-producing cells healthier for a longer period of time.

A signature for early-stage heart failure could improve diagnosis and prevent disease progression

September 30, 2014 – 8:53 am | Edit Post

Metabolic signature identifies early heart failure in mice.

ZMapp Ebola Drug Production Set for Texas, Possibly North Carolina

September 30, 2014 – 5:00 am | Edit Post

A federal initiative to ensure that the United States can respond to biological threats at home will be put to the test in response to the Ebola outbreak in West Africa. A Texas site is preparing to…

[[Click headline to continue reading.]]

Salk scientists receive $3 million for BRAIN Initiative grant

September 29, 2014 – 5:00 pm | Edit Post

LA JOLLA—Joseph Ecker, a Salk professor and Howard Hughes Medical Institute investigator, and Margarita Behrens, Salk staff scientist, have been named recipients in the 2014 round of grants from the National Institutes of Health (NIH) through the BRAIN (Brain Research through Advancing Innovative Neurotechnologies) Initiative for leading-edge work in neuroscience. The grant, announced September 30, provides more than $3 million in funding to the Salk scientists over three years.